CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Income (Loss)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenues | $76,201 | $138,103 |
| Operating expenses: | ||
| Research and development | 68,728 | 83,382 |
| General and administrative | 29,837 | 29,726 |
| Total operating expenses | 98,565 | 113,108 |
| Income (loss) from operations | (22,364) | 24,995 |
| Interest income | 5,206 | 7,136 |
| Other income (expense), net | 28 | (38) |
| Income (loss) before income taxes | (17,130) | 32,093 |
| Provision for income taxes | 238 | 224 |
| Net income (loss) | (17,368) | 31,869 |
| Deemed dividend on warrants | (3,002) | — |
| Net income (loss) attributable to common stockholders | $(20,370) | $31,869 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available-for-sale investments, net of tax | 84 | (68) |
| Total comprehensive income (loss) | $(17,284) | $31,801 |
| Net income (loss) per share: | ||
| Basic | $(0.15) | $0.38 |
| Diluted | $(0.15) | $0.38 |
| Weighted average common shares used to compute net income (loss) per share | ||
| Basic | 137,935,873 | 84,439,303 |
| Diluted | 137,935,873 | 84,745,116 |
CYTOMX THERAPEUTIC, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.